Yes, there is no absolute contraindication to using GLP-1 receptor agonists with Hashimoto's disease
What Triggered the Advisory The CDSCO advisory is prompted by a wave of multimedia obesity awareness campaigns launched by major pharmaceutical companies that, while stopping short of directly naming or promoting their drugs, were building public awareness around obesity as a disease and encouraging people to consult doctors, a strategy widely understood in the industry as a way to generate demand for GLP-1 therapies without technically violating India's prohibition on direct-to-consumer drug advertising
However, Wegovy 7.2mg (approved in the UK January 2026) produces 20.7% average weight loss at 72 weeks, which is comparable to Mounjaros highest dose
Common dosing mistakes and how to avoid them Dosing errors with compounded semaglutide are preventable
Stacking means using both compounds during the same treatment period, not necessarily on the same day
Oral B12 looks cheap, but if your body absorbs very little of each pill because of low stomach acid or a gut condition, much of that spending does not translate into results, and you keep buying bottle after bottle